Clonal Selection of a Novel Deleterious TP53 Somatic Mutation Discovered in ctDNA of a KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumor Resistant to Imatinib

The standard of care for the first-line treatment of advanced gastrointestinal stromal tumor (GIST) is represented by imatinib, which is given daily at a standard dosage until tumor progression. Resistance to imatinib commonly occurs through the clonal selection of genetic mutations in the tumor DNA...

詳細記述

保存先:
書誌詳細
出版年:Front Pharmacol
主要な著者: Dalle Fratte, Chiara, Guardascione, Michela, De Mattia, Elena, Borsatti, Eugenio, Boschetto, Roberta, Farruggio, Angelo, Canzonieri, Vincenzo, Romanato, Loredana, Borsatti, Rachele, Gagno, Sara, Marangon, Elena, Polano, Maurizio, Buonadonna, Angela, Toffoli, Giuseppe, Cecchin, Erika
フォーマット: Artigo
言語:Inglês
出版事項: Frontiers Media S.A. 2020
主題:
Pharmacology
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7019050/
https://ncbi.nlm.nih.gov/pubmed/32116712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.00036
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料